艾迪药业：2025年预亏约1600万元到2400万元

Core Viewpoint - Eddie Pharmaceuticals (688488) expects a net loss attributable to shareholders of approximately 16 million to 24 million yuan for 2025, compared to a loss of 141 million yuan in the same period last year [1] Financial Performance - The increase in sales expenses by approximately 92 million yuan compared to the previous year is attributed to the company's intensified efforts in new drug promotion and the consolidation of Nanda Pharmaceuticals' operating data [1] - The company is required to pay back taxes totaling approximately 19.95 million yuan, which will be included in the 2025 profit and loss statement, impacting the total profit for 2025 by about 19.95 million yuan [1]